DuBiotech's Dh289m Nucleotide Complex to open in September

DuBiotech's Dh289m Nucleotide Complex to open in September

Last updated:

Dubai: Dubai Biotechnology and Research Park (DuBio-tech), a member of Tecom Investments, yesterday said its laboratory buildings - the Dh289 million Nucleotide Complex - will be operational in September.

As the region's first dedicated modern laboratory compound, the Nucleotide Complex will offer flexible laboratory space for research.

Consisting of 'A, C, T and G' wings, the facility has been named after the four basic building blocks of nucleic acids, the main components of genetic material.

The four-storey complex has been designed by CUH2A, a leader in designing facilities for science and technology institutions.

Dr. Abdul Qader Al Khayat, executive director of DuBiotech, said: "The Nucleotide Complex demonstrates DuBiotech's serious commitment to developing sustainable buildings that accommodate leading clinical research institutions.

"In conformity with Tecom's overall strategy, the complex is already classified as a LEED-certified 'green' building, reflecting our social and environmental responsibility objectives.

"In addition to its modern amenities, the Nucleotide Complex will house the region's first pre-clinical vivarium, a laboratory for animal testing, spread over 10,000 square feet. This is the first time companies engaged in animal testing will have a facility dedicated to this type of research."

The Nucleotide Complex will allow companies to carry out laboratory-based research and analysis without the need to build their own dedicated facilities.

All DuBiotech subsidiary laboratories located at the facility are required to follow GLP and ISO 17025 standards, while all laboratory activities are strictly regulated by the Regulatory Affairs department.

At present, 28 companies licenced by DuBiotech are fully operational in the free zone. The park is working closely with the UAE ministry of health, the Dubai Health Authority, and other regulators to develop the life sciences industry.

Get Updates on Topics You Choose

By signing up, you agree to our Privacy Policy and Terms of Use.
Up Next